These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 25620635)

  • 21. Role of adipose tissue for cardiovascular-renal regulation in health and disease.
    Engeli S; Sharma AM
    Horm Metab Res; 2000; 32(11-12):485-99. PubMed ID: 11246814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of obesity-associated cardiovascular and renal disease.
    Hall JE; Crook ED; Jones DW; Wofford MR; Dubbert PM
    Am J Med Sci; 2002 Sep; 324(3):127-37. PubMed ID: 12240710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The metabolic syndrome as a prohypertensive state.
    Mulé G; Cerasola G
    Am J Hypertens; 2008 Jan; 21(1):8. PubMed ID: 18268791
    [No Abstract]   [Full Text] [Related]  

  • 24. Renal consequences of obesity.
    Naumnik B; Myśliwiec M
    Med Sci Monit; 2010 Aug; 16(8):RA163-70. PubMed ID: 20671624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
    Lambers Heerspink HJ; Perkovic V; de Zeeuw D
    J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mediators of sympathetic activation in metabolic syndrome obesity.
    Straznicky NE; Eikelis N; Lambert EA; Esler MD
    Curr Hypertens Rep; 2008 Dec; 10(6):440-7. PubMed ID: 18959829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Scope and mechanisms of obesity-related renal disease.
    Hunley TE; Ma LJ; Kon V
    Curr Opin Nephrol Hypertens; 2010 May; 19(3):227-34. PubMed ID: 20134323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease.
    Wahba IM; Mak RH
    Clin J Am Soc Nephrol; 2007 May; 2(3):550-62. PubMed ID: 17699463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders.
    Garg R; Adler GK
    Curr Hypertens Rep; 2015 Jul; 17(7):52. PubMed ID: 26068659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kidney disease and the metabolic syndrome.
    Zhang R; Liao J; Morse S; Donelon S; Reisin E
    Am J Med Sci; 2005 Dec; 330(6):319-25. PubMed ID: 16355017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obesity hypertension: the emerging role of leptin in renal and cardiovascular dyshomeostasis.
    Kshatriya S; Reams GP; Spear RM; Freeman RH; Dietz JR; Villarreal D
    Curr Opin Nephrol Hypertens; 2010 Jan; 19(1):72-8. PubMed ID: 19851106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The insulin resistance syndrome: mechanisms of clustering of cardiovascular risk.
    Chan JC; Tong PC; Critchley JA
    Semin Vasc Med; 2002 Feb; 2(1):45-57. PubMed ID: 16222595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overweight, hypertension and cardiovascular disease: focus on adipocytokines, insulin, weight changes and natriuretic peptides.
    Seven E
    Dan Med J; 2015 Nov; 62(11):B5163. PubMed ID: 26522487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular and renal surrogate markers in the clinical management of hypertension.
    Maisel AS
    Cardiovasc Drugs Ther; 2009 Aug; 23(4):317-26. PubMed ID: 19572190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of obesity as an independent risk factor for the development of renal injury: implications from rat models of obesity.
    McPherson KC; Shields CA; Poudel B; Fizer B; Pennington A; Szabo-Johnson A; Thompson WL; Cornelius DC; Williams JM
    Am J Physiol Renal Physiol; 2019 Feb; 316(2):F316-F327. PubMed ID: 30539649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aliskiren as a novel therapeutic agent for hypertension and cardio-renal diseases.
    Rashikh A; Ahmad SJ; Pillai KK; Najmi AK
    J Pharm Pharmacol; 2012 Apr; 64(4):470-81. PubMed ID: 22420653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determinants of increased cardiovascular disease in obesity and metabolic syndrome.
    Vazzana N; Santilli F; Sestili S; Cuccurullo C; Davi G
    Curr Med Chem; 2011; 18(34):5267-80. PubMed ID: 22087824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hypertension and renal disease].
    Kamper AL; Pedersen EB; Strandgaard S
    Ugeskr Laeger; 2009 Jun; 171(25):2109-13. PubMed ID: 19671393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obesity and insulin resistance in resistant hypertension: implications for the kidney.
    Rao A; Pandya V; Whaley-Connell A
    Adv Chronic Kidney Dis; 2015 May; 22(3):211-7. PubMed ID: 25908470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Visceral obesity, hypertension and cardio-renal risk: a review].
    Rosa EC; Zanella MT; Ribeiro AB; Kohlmann Junior O
    Arq Bras Endocrinol Metabol; 2005 Apr; 49(2):196-204. PubMed ID: 16184247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.